O	0	11	Thyrotropin	Thyrotropin	NN	B-NP
O	12	20	receptor	receptor	NN	I-NP
O	20	21	:	:	:	O
O	22	23	a	a	DT	B-NP
O	24	28	role	role	NN	I-NP
O	29	32	for	for	IN	B-PP
B-Organ	33	40	thyroid	thyroid	JJ	B-NP
O	41	55	tumourigenesis	tumourigenesis	NN	I-NP
O	55	56	?	?	.	O

O	58	63	Human	Human	JJ	B-NP
B-Cancer	64	71	thyroid	thyroid	JJ	I-NP
I-Cancer	72	79	tumours	tumour	NNS	I-NP
O	80	89	represent	represent	VBP	B-VP
O	90	92	an	an	DT	B-NP
O	93	100	example	example	NN	I-NP
O	101	103	of	of	IN	B-PP
O	104	107	the	the	DT	B-NP
O	108	117	interplay	interplay	NN	I-NP
O	118	120	of	of	IN	B-PP
O	121	128	genetic	genetic	JJ	B-NP
O	129	132	and	and	CC	I-NP
O	133	136	non	non	JJ	I-NP
O	137	144	genetic	genetic	JJ	I-NP
O	145	159	carcinogenesis	carcinogenesis	NN	I-NP
O	159	160	.	.	.	O

O	161	169	Recently	Recently	RB	B-ADVP
O	169	170	,	,	,	O
O	171	178	genetic	genetic	JJ	B-NP
O	179	192	abnormalities	abnormality	NNS	I-NP
O	193	195	in	in	IN	B-PP
O	196	199	the	the	DT	B-NP
O	200	208	elements	element	NNS	I-NP
O	209	211	of	of	IN	B-PP
O	212	215	the	the	DT	B-NP
O	216	227	Thyrotropin	Thyrotropin	NN	I-NP
O	228	236	receptor	receptor	NN	I-NP
O	237	238	(	(	(	O
O	238	241	TSH	TSH	NN	B-NP
O	241	242	-	-	HYPH	I-NP
O	242	243	R	R	NN	I-NP
O	243	244	)	)	)	I-NP
O	245	254	dependent	dependent	JJ	I-NP
O	255	259	cAMP	cAMP	NN	I-NP
O	260	270	regulatory	regulatory	JJ	I-NP
O	271	278	cascade	cascade	NN	I-NP
O	279	283	have	have	VBP	B-VP
O	284	288	been	be	VBN	I-VP
O	289	294	found	find	VBN	I-VP
O	295	297	to	to	TO	I-VP
O	298	300	be	be	VB	I-VP
O	301	309	involved	involve	VBN	I-VP
O	310	314	both	both	CC	O
O	315	317	in	in	IN	B-PP
B-Pathological_formation	318	324	benign	benign	JJ	B-NP
O	325	328	and	and	CC	I-NP
B-Cancer	329	338	malignant	malignant	JJ	I-NP
I-Cancer	339	346	thyroid	thyroid	JJ	I-NP
I-Cancer	347	354	tumours	tumour	NNS	I-NP
O	354	355	.	.	.	O

O	356	359	The	The	DT	B-NP
O	360	368	presence	presence	NN	I-NP
O	369	371	of	of	IN	B-PP
O	372	382	activating	activate	VBG	B-NP
O	383	392	mutations	mutation	NNS	I-NP
O	393	396	has	have	VBZ	B-VP
O	397	401	been	be	VBN	I-VP
O	402	414	demonstrated	demonstrate	VBN	I-VP
O	415	417	in	in	IN	B-PP
O	418	421	the	the	DT	B-NP
O	422	425	TSH	TSH	NN	I-NP
O	425	426	-	-	HYPH	B-NP
O	426	427	R	R	NN	I-NP
O	428	432	gene	gene	NN	I-NP
O	433	435	as	as	RB	B-CONJP
O	436	440	well	well	RB	I-CONJP
O	441	443	as	as	IN	I-CONJP
O	444	446	in	in	IN	B-PP
O	447	450	the	the	DT	B-NP
O	451	453	Gs	Gs	NN	I-NP
O	454	459	alpha	alpha	SYM	B-NP
O	460	467	protein	protein	NN	I-NP
O	468	472	gene	gene	NN	I-NP
O	473	475	in	in	IN	B-PP
B-Cancer	476	483	thyroid	thyroid	JJ	B-NP
I-Cancer	484	489	toxic	toxic	JJ	I-NP
I-Cancer	490	497	adenoma	adenoma	NN	I-NP
O	498	507	resulting	result	VBG	B-VP
O	508	510	in	in	IN	B-PP
O	511	514	the	the	DT	B-NP
O	515	527	constitutive	constitutive	JJ	I-NP
O	528	538	activation	activation	NN	I-NP
O	539	541	of	of	IN	B-PP
O	542	545	the	the	DT	B-NP
O	546	550	cAMP	cAMP	NN	I-NP
O	551	558	pathway	pathway	NN	I-NP
O	559	562	and	and	CC	O
O	563	565	it	it	PRP	B-NP
O	566	569	has	have	VBZ	B-VP
O	570	574	been	be	VBN	I-VP
O	575	587	hypothesised	hypothesise	VBN	I-VP
O	588	592	that	that	IN	B-SBAR
O	593	598	these	these	DT	B-NP
O	599	606	genetic	genetic	JJ	I-NP
O	607	618	alterations	alteration	NNS	I-NP
O	619	622	may	may	MD	B-VP
O	623	627	play	play	VB	I-VP
O	628	629	a	a	DT	B-NP
O	630	639	causative	causative	JJ	I-NP
O	640	644	role	role	NN	I-NP
O	645	647	in	in	IN	B-PP
O	648	651	the	the	DT	B-NP
O	652	659	disease	disease	NN	I-NP
O	659	660	.	.	.	O

O	661	668	However	However	RB	B-ADVP
O	668	669	,	,	,	O
O	670	676	recent	recent	JJ	B-NP
O	677	689	observations	observation	NNS	I-NP
O	690	697	suggest	suggest	VBP	B-VP
O	698	702	more	more	JJR	B-NP
O	703	710	caution	caution	NN	I-NP
O	711	713	in	in	IN	B-PP
O	714	723	accepting	accept	VBG	B-VP
O	724	728	such	such	PDT	B-NP
O	729	730	a	a	DT	I-NP
O	731	741	hypothesis	hypothesis	NN	I-NP
O	741	742	.	.	.	O

O	743	746	The	The	DT	B-NP
O	747	755	presence	presence	NN	I-NP
O	756	758	of	of	IN	B-PP
O	759	769	activating	activate	VBG	B-VP
O	770	773	TSH	TSH	NN	B-NP
O	773	774	-	-	HYPH	B-NP
O	774	775	R	R	NN	I-NP
O	776	785	mutations	mutation	NNS	I-NP
O	786	789	has	have	VBZ	B-VP
O	790	794	also	also	RB	I-VP
O	795	799	been	be	VBN	I-VP
O	800	812	demonstrated	demonstrate	VBN	I-VP
O	813	815	in	in	IN	B-PP
O	816	830	differentiated	differentiate	VBN	B-NP
B-Cancer	831	838	thyroid	thyroid	JJ	I-NP
I-Cancer	839	849	carcinomas	carcinoma	NNS	I-NP
O	849	850	.	.	.	O

O	851	853	At	At	IN	B-PP
O	854	861	present	present	NN	B-NP
O	861	862	,	,	,	O
O	863	866	the	the	DT	B-NP
O	867	877	percentage	percentage	NN	I-NP
O	878	880	of	of	IN	B-PP
O	881	885	such	such	JJ	B-NP
O	886	887	a	a	DT	I-NP
O	888	900	modification	modification	NN	I-NP
O	901	903	is	be	VBZ	B-VP
O	904	907	low	low	JJ	B-ADJP
O	907	908	,	,	,	O
O	909	915	unless	unless	IN	B-SBAR
O	916	924	referred	refer	VBN	B-VP
O	925	927	to	to	TO	B-PP
O	928	936	selected	select	VBN	B-NP
O	937	943	series	series	NN	I-NP
O	944	946	of	of	IN	B-PP
B-Cancer	947	954	tumours	tumour	NNS	B-NP
O	954	955	.	.	.	O

O	956	966	Activating	Activate	VBG	B-VP
O	967	976	mutations	mutation	NNS	B-NP
O	977	979	of	of	IN	B-PP
O	980	983	the	the	DT	B-NP
O	984	987	TSH	TSH	NN	I-NP
O	987	988	-	-	HYPH	B-NP
O	988	989	R	R	NN	I-NP
O	990	994	gene	gene	NN	I-NP
O	995	999	have	have	VBP	B-VP
O	1000	1004	been	be	VBN	I-VP
O	1005	1013	detected	detect	VBN	I-VP
O	1014	1016	in	in	IN	B-PP
O	1017	1018	a	a	DT	B-NP
O	1019	1024	group	group	NN	I-NP
O	1025	1027	of	of	IN	B-PP
O	1028	1042	differentiated	differentiate	VBN	B-NP
B-Cancer	1043	1053	carcinomas	carcinoma	NNS	I-NP
O	1054	1058	with	with	IN	B-PP
O	1059	1063	high	high	JJ	B-NP
O	1064	1069	basal	basal	JJ	I-NP
O	1070	1078	adenylyl	adenylyl	NN	I-NP
O	1079	1086	cyclase	cyclase	NN	I-NP
O	1087	1095	activity	activity	NN	I-NP
O	1095	1096	,	,	,	O
O	1097	1100	and	and	CC	O
O	1101	1103	in	in	IN	B-PP
O	1104	1105	a	a	DT	B-NP
O	1106	1109	few	few	JJ	I-NP
O	1110	1115	cases	case	NNS	I-NP
O	1116	1118	of	of	IN	B-PP
O	1119	1135	hyperfunctioning	hyperfunctione	VBG	B-VP
B-Cancer	1136	1143	thyroid	thyroid	JJ	B-NP
I-Cancer	1144	1153	carcinoma	carcinoma	NN	I-NP
O	1153	1154	.	.	.	O

O	1155	1162	However	However	RB	B-ADVP
O	1162	1163	,	,	,	O
O	1164	1167	the	the	DT	B-NP
O	1168	1172	role	role	NN	I-NP
O	1173	1175	of	of	IN	B-PP
O	1176	1179	the	the	DT	B-NP
O	1180	1183	TSH	TSH	NN	I-NP
O	1183	1184	-	-	HYPH	B-NP
O	1184	1185	R	R	NN	I-NP
O	1185	1186	-	-	HYPH	B-NP
O	1186	1193	related	relate	VBN	I-NP
O	1194	1198	cAMP	cAMP	NN	I-NP
O	1199	1206	pathway	pathway	NN	I-NP
O	1207	1218	alterations	alteration	NNS	I-NP
O	1219	1221	in	in	IN	B-PP
B-Organ	1222	1229	thyroid	thyroid	JJ	B-NP
O	1230	1244	transformation	transformation	NN	I-NP
O	1245	1252	remains	remain	VBZ	B-VP
O	1253	1255	to	to	TO	I-VP
O	1256	1258	be	be	VB	I-VP
O	1259	1269	elucidated	elucidate	VBN	I-VP
O	1269	1270	.	.	.	O

O	1271	1273	In	In	IN	B-PP
O	1274	1278	this	this	DT	B-NP
O	1279	1285	review	review	NN	I-NP
O	1285	1286	,	,	,	O
O	1287	1290	the	the	DT	B-NP
O	1291	1295	role	role	NN	I-NP
O	1296	1298	of	of	IN	B-PP
O	1299	1302	TSH	TSH	NN	B-NP
O	1302	1303	-	-	HYPH	B-NP
O	1303	1304	R	R	NN	I-NP
O	1305	1309	gene	gene	NN	I-NP
O	1310	1321	alterations	alteration	NNS	I-NP
O	1322	1324	in	in	IN	B-PP
B-Pathological_formation	1325	1331	benign	benign	JJ	B-NP
O	1332	1335	and	and	CC	I-NP
B-Cancer	1336	1345	malignant	malignant	JJ	I-NP
I-Cancer	1346	1353	thyroid	thyroid	JJ	I-NP
I-Cancer	1354	1363	neoplasia	neoplasia	NN	I-NP
O	1364	1366	is	be	VBZ	B-VP
O	1367	1375	examined	examine	VBN	I-VP
O	1375	1376	.	.	.	O

